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1183-151 Outcomes of Percutaneous Intervention in Cardiac 
Allograft Vaaculopathy 
David M. Casev, Randall C, Starling, Murat Tuzcu, Cleveland Clinic Foundation, 
Cleveland, Ohio. 
Background: In heart transplant patients surviving >1 year after transplantation, cardiac 
allograft vasculopathy (CAV) remains the leading cause of death. Percutaneous interven- 
tion, which has proven effective in native vessel disease, is being increasingly used in 
the treatment of CAV, however the long term clinical and angiographic outcomes are 
largely unknown. 
Methods: Between January 1995 and December 2000, 27 patients at our institution 
underwent percutaneous intervention for 48 coronary lesions. There were 25 slanting 
procedures and 23 psrcutaneous transluminal coronary angioplasty (PTCA) procedures, 
with or without atheroablation. Forty of the lesions were de nova. Routine follow-up 
angiograms were obtained at 12 months; angiography was performed earlier if clinically 
indicated. Restenosis was defined as >50% narrowing of the target vessel segment. 
Data was collected on the clinical endpoints of cardiac death, non-fatal myocardial infarc- 
tion, or need for surgical revascularization. 
Results: Procedural success was 96% (46/48), and there were no major complications. 
Clinical follow-up was available for all 27 patients. One patient died 12 days poststent of 
a cardiac arrest, one patient suffered a nonfatal myocardial infarction 13 months posts- 
tent, and two patients required bypass grafting; one 5 months poststent and the other 12 
months postPTCNatherectomy. No patients were retransplanted. Follow-up angiography 
was available for 78% of the intervened segments. The restenosis rate for all types of 
intervention was 47%(17/36) at a mean follow-up time of 20.4+13.8 months. Restenosis 
was seen in 41%(7/17) of stented lesions and in 53%(10/19) of PTCA lesions, not a sta- 
tistically significant difference. 
Conclusion'=: Percutaneous intervention for the treatment of CAV can be performed 
safely with high procedural success rates. Restenosis rates are higher than what is seen 
in native vessel intervention, however the clinical event rate is low. The restenosis rates 
for PTCA and slant are approximately equivalent. A larger number of patients needs to 
be evaluated to determine the most efficacious approach in using percutaneous interven- 
tion for CAV. 
1183-152 Left Ventricular Systolic Function Early After Heart 
Transplantation Is Related to Subsequent Cardiac 
AIIograft Vasculopathy 
Islam A. Bolad. Derek Robinson, Asghar Khaghani, Nicholas R. Banner, Harefield 
Hospital, Harefield, United Kingdom. 
Background: Cardiac allograft injury at the time of transplantation may be related to 
subsequent cardiac allograft vasculopathy (CAV). We investigated whether the left ven- 
tricular systolic function early after heart transplantation is related to subsequent devel- 
opment of CAV. 
Methods: We measured the echocardiographic left ventricular fractional shortening (FS) 
during the first week after transplantation in 117 patients and performed quantitative cor- 
onary angiography (QCA) within 4 weeks and again 1 year after transplantation. Anglo- 
grams were obtained using a standardised technique after intracoronary GTN. 
Results: Ninety-eight patients were males (83.8%) and 19 were females (16.2%); the 
mean age was 48.4±10.1years. 110 (94%) patients were Caucasian. The cause of the 
heart failure, which necessitated transplantation, was ischaemic in 71(61%) patients, 
idiopathic dilated cardiomyopathy in 28 (24%), congenital in 6 (5%) and other causes in 
12 (10%) patients. The total organ ischaemia time during transplantation was 155±57 
minutes. The outcome measure was loss of absolute lumen diameter determined by 
QCA. The initial FS was 35±7 %, with a median of 35%. The table below shows the 
strong relationship between the FS early after operation and narrowing of the epicardial 
coronary arteries during the first year after transplantation. 
Year initial FS n Mean decrease in diameter (mm) SEM p-value 
0 to 1 _<35% 60 0.290 0.034 0.0098 
0to 1 >35% 57 0.164 0.034 
Conclusion: Improvements in myocardial protection and methods that reduce 
ischaemia-reperfusion injury during transplantation may reduce the risk of subsequent 
CAV. 
1183-171 The Relationship of A I Iogref t  In f lammatory  Factor-1 
(AIF-f) Expression to Rejection Grade in 
Endomyocardial Biopsies From Cardiac Ailograft 
Recipients 
Howard J. Eisen. Shed E. Kelemen, Michael V. Autieri, Temple University School of 
Medicine, Philadelphia, Pennsylvania. 
Background: Cardiac allograft vasculopathy (CAV) is a major sequela of cardiac transplan- 
tation which limits the long time survival of cardiac transplant recipients. The initiation of 
CAV is believed to involve a chronic immune response of the recipient to the donor vascu- 
lature in which activated immune cells damage the endothelium, resulting in the elabora- 
tion of cytokines and modulation of arterial medial vascular smooth muscle cell (VSMC) 
gene expression. These cytokines elicit the activation of VSMCs which migrate into the inti- 
mal layer and proliferate, causing the vascular narrowing seen in CAV. This cytokine- 
induced activation and proliferation of medial VSMCs is one of the most critical cellular 
events in the pathogenesis of CAV. Allograff Inflammatory Factor-1 (AIF-1) is a 147 amino 
acid calcium-binding protein which was originally identified and cloned from rat cardiac 
allografts with chronic rejection. It has previously been shown to be induced in cultured 
human VSMCs stimulated with a variety of inflammatory cytokines. Further, over-expres- 
sion of AIF-1 results in enhanced growth and activation of VSMCs. The relationship of AIF- 
ABSTRACTS- Cardiac Function and Heart Failure 189A 
1 expression to acute cellular rejection is not well understood. Methods: To further explore 
the relationship of AIF-1 gene expression to allograft rejection, we studied 235 endomyo- 
cardial biopsies from 34 cardiac transplant patients for expression of AIF-1 using reverse- 
transcriptase polymerase chain reaction (RT-PCR). GAPDH, a constitutively expressed 
control gene, was used to determine the presence of mRNA in biopsy specimens. Results: 
The percentage of biopsies expressing AIF-1 as a function of ISHLT grade were:Grade 0- 
11/56 (19.6%); Grades 1A and 1B- 24/61 (39.3%); Grade 2- 14/18 (77.8%); Grades 3A 
and 3B- 12121 (57.1%). AIF-1 expression was enhanced with more severe ISHLT rejection 
grades. Conclusion: We conclude that AIF-1 expression is enhanced as a result of cellular 
rejection. This enhanced expression, ff persistent, may link the presence of significant 
ISHLT grade rejection episodes to the subsequent development of CAV. 
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1184-137 Blunted Heart Rate Recovery Fails to Predict Coronary 
Events in Apparently Healthy Individuals 
Jerome L. Fled, Rouzbeh Tehrani, Frances E. O'Connor, Jeanetta G. Wright, National 
Institute on Aging, Baltimore, MD. 
Backaround: Blunted heart rate (HR) recovery from exercise has been shown to predict 
all-cause mortality. However, its effect on cardiac end-points is not known. 
Methods: We analyzed HR recovery from maximal treadmill exercise (modified Balke 
protocol) in 1052 subjects, aged 18-90 yr from the Baltimore Longitudinal Study on Aging 
from 1979 to 1996, were clinically free of heart disease. HR recovery was defined as the 
change in HR between peak exercise and 2 minutes post exercise (AHR2). 
Results: On linear regression analysis, AHR2 correlated inversely with age (r=-0.42), sit- 
ting HR (r=-0.31) and exercise duration (DUR)(r=-0.31), each p<.000t. Over a mean fol- 
low-up of 9.1 _+ 9.6 yr, coronary events (CE), i.e., angina pectoris, myocardial infarction, 
or coronary death, developed in 116 subjects. Those experiencing CE were older (65 -+ 
12 vs 52 ± 17 yr) and had shorter DUR(9.1 ± 2.7 vs 11.0 ± 2.8mini and smaller AHR2 (51 
+- 13 vs 57 +- 13 beats/mini each p<.000t han those who remained event-frae. The inde- 
pendent predictors of CE were determined from a Cox proportional hazards model 
including age, gender, plasma cholesterol (CHOL), hypertension status, smoking status, 
DUR, exercise-induced ischemic ST segment depression (ST-D)and AHR2 (Table). 
Model chl square 2=113.0, p<0.0001 
AGE GENDER CHOL DUR ST-D DHR2 
Risk Ratio 1.04 2.16 1.01 0,886 1.71 0.997 
p 0.0001 0.001 0,0002 0.003 0.03 0.72 
A similar lack of significance was observed when quartUes of AHR2 were substituted for 
absolute values in this model. 
Conclusions: A blunted DHR2 is not significant predictor of CE in apparently healthy indi- 
viduals, independent of conventional risk factors. 
1184-138 Diabetes Mellitus and Abnormal Heart Rate Recovery in 
Patients Without Coronary Artery Disease 
Niranian Seshadri, Naveen Acharya, Michael S. Lauar, Cleveland Clinic Foundation, 
Cleveland, Ohio. 
Background: Diabetes mellitus (DM) is associated with autonomic dysfunction. Heart 
rate recovery (HRR) after exercise is an easily obtained measure that correlates with 
decreased parasympathetic function and is known to predict mortality, We sought to 
determine if DM is independently associated with an abnormal HRR. 
Methods: We analyzed 1817 consecutive patients who underwent symptom-limitad 
exercise testing as part of a routine screening program. None had history of coronary dis- 
ease. HRR was defined as a fall in heart rate during the first minute after exercise of_< 12 
beats/minute. DM was defined as a fasting blood glucose _> 126 mg/dl or use of hypogly- 
cemic drugs. 
Results: There were 51 patients (2%) who had DM, while 168 (9%) had an abnormal 
HRR. Increasing blood sugar levels were associated with an abnormal HRR, especially 
at diabetic levels (Figure). Patients with DM were more likely to have an abnormal HRR 
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